Treatment of Secondary Hyperparathyroidism in Stage 5D CKD

Secondary hyperparathyroidism (SHPT) in the setting of advanced chronic kidney disease requires a structured medical approach to bring intact PTH into an acceptable range and reduce the risk of associated complications.

Clinical Target

The goal is to bring intact PTH within a target range of 130–600 pg/mL — approximately 2 to 9 times the upper normal limit — in patients with stage 5D CKD.

Treatment Approach

Medical management centres on combining phosphorus binders with a PTH-lowering agent. Multiple agent classes are available for PTH reduction; the appropriate selection depends on the individual clinical picture.

Full agent selection, sequencing, and clinical criteria are detailed in the structured protocol — see below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3389/fendo.2023.1169793

For the treatment of SHPT, phosphorus binders and vitamin D receptor activators were developed; however, they were ineffective in cases of severe SHPT.
In the KDIGO 2017 clinical practice guideline update, medical therapy using calcimimetics, calcitriol, or vitamin D analogs are additionally suggested as PTH-lowering therapy.
In the KDIGO guidelines, the target range for intact PTH levels is within 2–9 times the upper normal range for patients with stage 5D CKD, equivalent to 130–600 pg/mL.

View source ↗